MedPath
HSA Approval

TIDACT INJECTION 150 mg/ml

SIN07759P

TIDACT INJECTION 150 mg/ml

TIDACT INJECTION 150 mg/ml

July 1, 1994

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Regulatory Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Therapeutic

Prescription Only

Formulation Information

INJECTION

**Dosage and Administration:** Single I.M. injection should not exceed 600mg; for I.V. infusion, do not administer more than 1200mg in a single 1 hour infusion. Adult dose: I.M. or I.V. Ordinary infections: 600–1200mg/day in 2,3 or 4 equal doses. Serious infections: 1200–1800mg/day in 3 or 4 equal doses. Very serious infections: 2400–2700mg/day in 2,3 or 4 equal doses. In life threatening situations, a maximum of 4800mg/day may be given I.V. May be administered as a single rapid infusion on the first dose and followed by continuous I.V. infusion, as follows: To maintain serum ![Tidact Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/5ba082c1f4d5ec3b00ff00204ec5e8f7.png) To prepare initial dilution for I.V. dose, each dose must be diluted as follows (it must not be administered undiluted as a bolus): ![Tidact Dosage Table 2](https://cdn.medpath.com/drug/dosage/20240520/864609d9da8c6eda679b451f8866b3cd.png) Children dose: I.M. or I.V. Infants up to 1 month of age: 15–20mg/kg/day in 3 or 4 equal doses. Over 1 month of age: 20–40mg/kg/day in 3 or 4 equal doses. May be given based on body surface area: Serious infections: 350mg/m2/day More serious infections: 450mg/m2/day In _β_-hemolytic streptococcal infection, treatment should be continued for at least 10 days. To be administered only by a physician.

INTRAVENOUS, INTRAMUSCULAR

Medical Information

**Indications:** For the treatment of serious infections due to susceptible strains of Staphylococci, Streptococci, Pneumococci, and anaerobic bacteria.

**Contraindications:** 1. History of gastrointestinal disease, especially ulcerative colitis, regional enteritis, and antibiotic-associated colitis. Clindamycin may cause pseudomembranous colitis. 2. Severe hepatic function impairment. Half-life of Clindamycin is prolonged in this condition, therefore may require dosage adjustment. 3. Hypersensitivity to Lincomycins and doxorubicin. 4. Severe renal function impairment may require reduction of dosage.

J01FF01

clindamycin

Manufacturer Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL IND CO LTD

Active Ingredients

CLINDAMYCIN PHOSPHATE EQV CLINDAMYCIN

150 mg/ml

Clindamycin

Documents

Package Inserts

Attachment 3 TDI- Proposed Clean PI.pdf

Approved: September 6, 2022

Download
© Copyright 2025. All Rights Reserved by MedPath
TIDACT INJECTION 150 mg/ml - HSA Approval | MedPath